Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 14, 2018 - Issue 3
Submit an article Journal homepage
365
Views
10
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson’s disease

Marina Svetela Clinic of Neurology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, SerbiaView further author information
,
Aleksandra Tomića Clinic of Neurology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, SerbiaView further author information
,
Nikola Kresojevićb Clinic of Neurology, Clinical Center of Serbia, Belgrade, SerbiaView further author information
&
Vladimir Kostića Clinic of Neurology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, SerbiaCorrespondence[email protected]
View further author information
Pages 353-360 | Received 15 Sep 2017, Accepted 16 Jan 2018, Published online: 24 Jan 2018

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Matthew Feldman & Jason Margolesky. (2023) Opicapone for the treatment of Parkinson’s disease: a review. International Journal of Neuroscience 133:5, pages 532-543.
Read now
András Salamon, Dénes Zádori, László Szpisjak, Péter Klivényi & László Vécsei. (2019) Opicapone for the treatment of Parkinson’s disease: an update. Expert Opinion on Pharmacotherapy 20:18, pages 2201-2207.
Read now
Nataša Dragašević-Mišković, Igor Petrović, Iva Stanković & Vladimir S. Kostić. (2019) Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy 20:2, pages 219-230.
Read now

Articles from other publishers (7)

Sergey V. Baykov, Anton A. Shetnev, Artem V. Semenov, Svetlana O. Baykova & Vadim P. Boyarskiy. (2023) Room Temperature Synthesis of Bioactive 1,2,4-Oxadiazoles. International Journal of Molecular Sciences 24:6, pages 5406.
Crossref
Amnon A. Berger, Ariel Winnick, Jonathan Izygon, Binil M. Jacob, Jessica S. Kaye, Rachel J. Kaye, Elisa E. Neuchat, Adam M. Kaye, Edward S. Alpaugh, Elyse M. Cornett, Andrew H. Han & Alan D. Kaye. (2022) Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes. Health Psychology Research 10:5.
Crossref
Amnon A. Berger, Christopher Robinson, Ariel Winnick, Jonathan Izygon, Binil M. Jacob, Mackenzie J. Noonan, Alan D. Kaye, Jessica S. Kaye, Adam M. Kaye, Elyse M. Cornett, Rutvij J. Shah, Omar Viswanath & Ivan Urits. (2021) Opicapone for the Treatment of Parkinson’s Disease "Off" Episodes: Pharmacology and Clinical Considerations. Clinical Drug Investigation 42:2, pages 127-135.
Crossref
Wei Xue, Yan Tan, Yue Liu, Changjiang Xu, Duanduan Cong, Liping Zhong, Jie Song, Aimin Hui, Wenyuan Qi, Juan Wang, Xiaohui Liu & Kexin Li. (2021) Pharmacokinetics of Opicapone and Its Metabolites in Healthy White and Chinese Subjects. Clinical Pharmacology in Drug Development 10:11, pages 1316-1324.
Crossref
Jane Price, Hannah Martin & Louise Ebenezer. (2021) Prescribing considerations in the use of oral medication in Parkinson's disease. Journal of Prescribing Practice 3:10, pages 396-403.
Crossref
Francesco Cavallieri, Valentina Fioravanti & Franco Valzania. (2021) Opicapone and acute levodopa challenge test: the big issue. Acta Neurologica Belgica 121:5, pages 1347-1349.
Crossref
Masahiro Nomoto, Atsushi Takeda, Katsuaki Iwai, Akihisa Nishimura & Nobutaka Hattori. (2020) Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study. Clinical Pharmacology in Drug Development 10:2, pages 173-179.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.